The S&P 500 plunged by 1.7% on Friday, Feb. 21, as weak economic data and earnings forecasts sent the benchmark index lower for the second straight session.
While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...
Bullish option flow detected in Moderna (MRNA) with 76,253 calls trading, 1.4x expected, and implied vol increasing almost 8 points to 77.82%. Feb-25 35 calls and Feb-25 34 calls are the most active ...
Snopes tried to discredit research as a "rumor" when journalist received early results from conference call between researchers and study participants. Spike still detectable in some participants ...
The Make America Healthy Again commission is taking action on mRNA vaccines as several states consider legislation to ban ...
In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to ...
As bad as it may look on the charts, Moderna’s (NASDAQ: MRNA) post-COVID let-down and market reset are over. The company ...
We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going to take a look at where Moderna, Inc.
UBS lowered the firm’s price target on Moderna (MRNA) to $78 from $96 and keeps a Buy rating on the shares. UBS believes Moderna’s oncology ...
The FDA is mired in uncertainty with some staffers losing their jobs over the weekend and more potentially to come, vaccines ...